BioMarin Pharmaceutical Inc.

Belkins
BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOMEME, INC. ANNOUNCES SARS-COV-2 TEST APPROVAL BY FDA UNDER THE EMERGENCY USE AUTHORIZATION

Biomeme | August 20, 2020

news image

Biomeme, Inc. announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus&r...

Read More

ACTICOR BIOTECH ANNOUNCES THE SUCCESS OF THE FIRST PHASE OF ITS ACTIMIS STUDY WITH GLENZOCIMAB IN PATIENTS WITH ACUTE ISCHEMIC STROKE

Acticor Biotech | October 05, 2020

news image

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy). 5 cohorts of patients presenting wit...

Read More

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

GEN | April 15, 2020

news image

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More

INDUSTRIAL IMPACT

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Navrogen Inc. | August 18, 2021

news image

Navrogen Inc. a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of various cancer indications. Under the agreement, Navrogen and Tavotek will...

Read More

Biomeme | August 20, 2020

news image

BIOMEME, INC. ANNOUNCES SARS-COV-2 TEST APPROVAL BY FDA UNDER THE EMERGENCY USE AUTHORIZATION

Biomeme, Inc. announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus&r...

Read More

Acticor Biotech | October 05, 2020

news image

ACTICOR BIOTECH ANNOUNCES THE SUCCESS OF THE FIRST PHASE OF ITS ACTIMIS STUDY WITH GLENZOCIMAB IN PATIENTS WITH ACUTE ISCHEMIC STROKE

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy). 5 cohorts of patients presenting wit...

Read More

GEN | April 15, 2020

news image

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More

INDUSTRIAL IMPACT

Navrogen Inc. | August 18, 2021

news image

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Navrogen Inc. a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of various cancer indications. Under the agreement, Navrogen and Tavotek will...

Read More